The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging

Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):2057-2058. doi: 10.1007/s00259-020-05184-0. Epub 2021 Jan 23.

Ann-Christin Eder^{1

2}, Mohamed A Omrane^{3

4}, Sven Stadlbauer^{5

6}, Mareike Roscher^{5

7}, Wael Y Khoder⁸, Christian Gratzke⁸, Klaus Kopka^{5

6

9

10}, Matthias Eder^{3

4}, Philipp T Meyer^{3

11}, Cordula A Jilg⁸, Juri Ruf^{3

11}

¹ Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ann-christin.eder@uniklinik-freiburg.de.
² Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, Germany and German Cancer Research Center, Heidelberg, Germany. ann-christin.eder@uniklinik-freiburg.de.
³ Department of Nuclear Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁴ Division of Radiopharmaceutical Development, German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, Germany and German Cancer Research Center, Heidelberg, Germany.
⁵ Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁶ Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
⁷ Division of Radiooncology/Radiobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁸ Department of Urology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁹ German Cancer Consortium (DKTK), partner site Dresden, Dresden, Germany.
¹⁰ Dresden University of Technology, Faculty of Chemistry and Food Chemistry, Dresden, Germany.
¹¹ German Cancer Consortium (DKTK), partner site Freiburg, Freiburg, Germany.

No abstract available

Publication types